SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Avalyn Pharma Ended 3Q With $386.6 M in Cash, Cash Equivalents and Marketable Securities >AVLN

AVLN

Related stories